<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03163784</url>
  </required_header>
  <id_info>
    <org_study_id>2016P002317</org_study_id>
    <nct_id>NCT03163784</nct_id>
  </id_info>
  <brief_title>SHIFT: Studying HIV Immunology After Fecal Transplant</brief_title>
  <acronym>SHIFT</acronym>
  <official_title>SHIFT: Studying HIV Immunology After Fecal Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SHIFT is a randomized, longitudinal, prospective, blinded, three-arm study to determine the
      safety and tolerability of Fecal Microbiota Transplant (FMT) in HIV-infected participants on
      stable antiretroviral therapy (ART).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to test the safety and tolerability of Fecal Microbiota Transplant
      (FMT) in HIV infected individuals on stable antiretroviral therapy (ART). Additionally, the
      study will examine potential effects of FMT on HIV immune activation, which has been linked
      to HIV disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FMT-related adverse events</measure>
    <time_frame>30 weeks</time_frame>
    <description>Safety of FMT in stably suppressed HIV infected recipients on ART</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune and metabolic markers</measure>
    <time_frame>30 weeks</time_frame>
    <description>Changes in immune and metabolic markers such as CD4 T cell activation and sCD14 levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiome structure</measure>
    <time_frame>30 weeks</time_frame>
    <description>Identify and characterize how FMT alters enteric microbiome structure.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>Dysbiosis</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Weekly placebo (for Fecal Inoculum Capsule) treatment with placebo pre-treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly Fecal Inoculum Capsule treatment with placebo pre-treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly Fecal Inoculum Capsule treatment with antibiotic pre-treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Inoculum Capsule</intervention_name>
    <description>Sieved fecal matter prepared in glycerol/saline solution</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo (for Fecal Inoculum Capsule)</intervention_name>
    <description>Placebo capsule manufactured to mimic Fecal Inoculum Capsules</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic</intervention_name>
    <description>Antibiotic pre-treatment</description>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic Placebo</intervention_name>
    <description>Placebo tablets manufactured to mimic antibiotics</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women ages 18 - 75 years.

          2. HIV-1 positive:

          3. Ability and willingness of participant or legal guardian/representative to provide
             informed consent.

        Exclusion Criteria:

          1. Patients with a history of significant allergy to tree nuts, peanuts, shellfish,
             and/or eggs, vancomycin, levofloxacin, or metronidazole, chocolate/cocoa or gelatin;
             or unwillingness to ingest gelatin (in placebo capsules)

          2. Use of investigational therapies or investigational vaccines within 90 days prior to
             study entry

          3. Serious illness requiring systemic treatment and/or hospitalization within 30 days
             prior to entry

          4. History of positive HCV antibody with detectable HCV RNA in plasma within 48 weeks
             prior to study entry.

          5. History of positive HBsAg within 48 weeks prior to study entry

          6. Liver cirrhosis, history of C. difficile infection, history of inflammatory bowel
             disease, bariatric surgery, total colectomy, colon or rectal anastomosis, bowel
             resection, or current colostomy.

          7. Current diagnosis of diabetes

          8. BMI &gt;35

          9. Either breastfeeding or pregnant within 24 weeks prior to study entry

         10. Tendinopathy or peripheral neuropathy (potentially exacerbated by antibiotic
             pretreatment)

         11. Use of immunosuppressives, immune modulators, or antineoplastic agents for more than 3
             consecutive days within the 60 days prior to study entry.

         12. Use of probiotics and prebiotics (supplements and products) within 30 days of the
             study. Yogurt with live cultures is allowed.

         13. Diagnosed bacterial enteric infection within 30 days prior to study entry.

         14. Acute diarrhea within 30 days of study entry.

         15. Weight loss or gain of more than 25 pounds in the 24 weeks prior to study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Kwon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zoe Rogers</last_name>
    <phone>8572687153</phone>
    <email>ZROGERS@PARTNERS.ORG</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kelly Judge</last_name>
    <phone>8572687066</phone>
    <email>kjudge2@mgh.harvard.edu</email>
  </overall_contact_backup>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2017</study_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Douglas Kwon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Dysbiosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

